SEC Tracker
Get the app

Harvard Bioscience HBIO

Harvard Bioscience reports Q3 2026 revenue growth of 8%

Harvard Bioscience (HBIO) filed an 8-K with the SEC on Nov 10, 2026, 7:00 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Q3 2026 revenue: $22.2 million, up 8% from $20.6 million in Q3 2025
  2. Full-year 2026 revenue guidance reaffirmed at 3%-5% growth
  3. Adjusted EBITDA for Q3 2026: $1.8 million, down from $2.0 million in Q3 2025
  4. Net loss for Q3 2026: $2.6 million, compared to $1.2 million in Q3 2025

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Harvard Bioscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.